Trial Profile
A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cu(II) ATSM (Primary)
- Indications Amyotrophic lateral sclerosis; Motor neuron disease
- Focus Adverse reactions; First in man
- Sponsors Collaborative Medicinal Development
- 01 May 2020 Results (n=19) of phase 1 and phase 2a parts of study were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 15 Mar 2020 Status changed from active, no longer recruiting to completed.
- 04 Nov 2019 Planned End Date changed from 30 Mar 2020 to 30 Dec 2019.